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Introduction
The disintegrin and metalloproteinase ADAM15 belongs to a large
family of about 40 homologous transmembrane glycoproteins that
share a common modular ectodomain architecture [1, 2]. The
extracellular components consist of a cysteine-rich region and a
disintegrin domain, which contributes to cell–cell interactions via
its capability to interact with alphav3, alpha51 and the alpha9
integrins [3–5], followed by a metalloproteinase module that is
capped by a large prodomain of about 200 amino acid residues [1,
2]. The cytoplasmic domain of ADAM15 contains SH3-binding
sites, which can potentially activate kinases of the src-kinase fam-
ily [6]. Although ADAM15 is not present in normal healthy tissues,
it gets up-regulated in tumourigenesis [7] as well as in other non-
neoplastic conditions of tissue remodelling such as atherosclero-
sis [8] and inflammatory as well as degenerative joint diseases [9,
10]. In the latter rheumatic conditions, high expression of
ADAM15 has been demonstrated in synovial fibroblasts, especially
in rheumatoid arthritis (RA), whereas chondrocytes exhibited
ADAM15 up-regulation already at very early stages of osteoarthri-
tis (OA) development [9, 10].
The precise role of ADAM15 in the pathogenesis of human OA
has remained enigmatic so far. However, some basic mechanisms
of potential relevance have already been elucidated. Thus,
ADAM15 contains in its metalloproteinase (MP) domain a com-
mon metalloproteinase consensus motif. It is thought that this
metalloproteinase is kept in an inactive conformation by the adja-
cent prodomain, which upon its own cleavage finally liberates the
active protease from latency [reviewed in 1]. Initial in vitro exper-
iments suggest that ADAM15 is indeed capable to cleave collagen
type IV [11], thereby indicating the potential of its catalytic domain
to contribute to pathologic extracellular matrix (ECM) remodelling.
However, more direct experimental support for such a role of
ADAM15 in proteolytic cartilage-degradation in vivo is missing.
Theoretically, the MP domain could also contribute to cartilage
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pathology via the proteolytic shedding of membrane-bound recep-
tor ligands in analogy to the proinflammatory effects of ADAM17
(TNFalpha converting enzyme) [reviewed in 12]. Although studies
of EGF-receptor (EGFR) transsignalling in tumour cells suggest a
respective potential of the ADAM15 MP domain to act as a shed-
dase of EGFR ligands [13], corresponding evidence for a similar
role in degenerative cartilage disease is entirely missing. Although
the function of the ADAM15 MP domain remains enigmatic, the
accelerated development of murine osteoarthritic lesions in
ADAM15-deficient mice compared with wild-type rather suggests a
homeostatic than a destructive role of ADAM15 in cartilage remod-
elling [14]. Accordingly, the more recently uncovered reinforce-
ment of integrin-dependent collagen II (CII) adhesion by ADAM15
overexpression in the human chondrocyte cell line T/C28a4 asso-
ciated with cell survival promoting effects in vitro [14] has gained
importance for a better understanding of ADAM15 up-regulation in
early OA cartilage. Therefore, the aim of the present study was to
identify the functional domain(s) of ADAM15 involved in the
enhanced CII binding by transfecting T/C28a4 chondrocytes with
full-length ADAM15 cDNA and its respective deletion mutants and
to characterize concomittant alterations of the outside-in signalling
during collagen adhesion. The results of our investigation uncover
the critical role of the prodomain for the capacity of ADAM15 to
reinforce chondrocyte-binding to CII thereby identifying for the first
time a direct function of a MP-prodomain for cell adhesion to ECM.
The cytoplasmic tail of ADAM15, although dispensible for the
enhanced CII adhesion, however, confers a modulatory effect on
outside-in signalling during chondrocyte–matrix interaction. Thus,
our results demonstrate that ADAM15 overexpression results in a
reduced phosphorylation at the critical autophosphorylation site at
Y397 in the non-receptor tyrosine kinase focal adhesion kinase
(FAK) localized to focal adhesions.
Materials and methods
Materials
Several antibodies directed against ADAM15 were used: a goat polyclonal
and a mouse monoclonal from R&D Systems (Wiesbaden, Germany), a rab-
bit polyclonal against the prodomain and against the cytoplasmatic domain
from Chemicon/Millipore (Schwalbach, Germany). Anti-pTyr99 antibody was
from Santa Cruz Biotechnology (Heidelberg, Germany). Anti-phospho Y397
FAK was from BioSource (Solingen, Germany), mouse monoclonal anti-FAK
(clone 4.47, Upstate-Millipore), rabbit anti-actin and mouse monoclonal anti-
Gst (clone Gst-2) from Sigma-Aldrich (Taufkirchen, Germany). Isotype-spe-
cific control antibodies were from AbD Serotec (Düsseldorf, Germany).
Bovine type II collagen was from Mdbiosciences (Egg, Switzerland), human
plasma fibronectin from Chemicon/Millipore. The chondrocyte cell line
T/C28a4 [15] was kindly provided by Dr. M.B. Goldring (Hospital for Special
Surgery, New York, NY, USA). Primary, non-passaged human chondrocytes
from either normal or osteoarthritic (OA) cartilage were kindly provided by
Dr. Thomas Aigner (Institute of Pathology, Leipzig, Germany) [16]. Although
the normal   cartilage was obtained from donors at autopsy not later than 
48 hrs post-mortem, the human OA specimens were derived from the hip or
knee joints of patients who had undergone endoprosthetic joint surgery for
severe osteoarthritis. Prior to use, the categorization of cartilage specimens
into normal or osteoarthritic had been validated by microscopic assessments
of an experienced pathologist (Dr. T. Aigner).
Cloning of full-length ADAM15 and deletion
mutants
Full-length ADAM15 was subcloned from the previously used pcDNA vector
containing the full-length sequence [14] into the pexchange-1 vector and a
puromycin cassette was inserted using the Cre recombinase according to
the supplier’s instructions (Stratagene, Amsterdam, The Netherlands). The
ADAM15 mutants were cloned accordingly into the pexchange-1 vector
using the full-length ADAM15 plasmid as template. Transmembrane-
anchored ADAM15 lacking the complete cytoplasmic domain (cyto) was
cloned using the primer pair 5 TCGGATCCCCCGGGCTGCAGGAATT3 and
5ACTCGAGTCAGTACCAGTAGCCGGCACCAA 3 for amplification. ADAM15
mutants either lacking the prodomain (Pro), or the pro- and MP-domain
(ProMP) were cloned using fusion PCR (polymerase chain reaction) and
the full-length ADAM15 plasmid as a template: in the first PCR step, the
nucleotide sequence encoding the signal peptide was amplified using
primer I 5TCGGATCCCCCGGGCTGCAGGAATT3 and primer II 5CACAAT-
CACCAACTCCACAGTCTTAGGCAGAGGGCTGCCCC3. In the second PCR, a
sequence starting at the 5start of the MP-domain (bp 639) was amplified
using primer III 5AAGACTGTGGAGTTGGTGATTGTG3 and primer IV
5CTCGAGGTCGACGGTATCGA3. In the following third step, the PCR prod-
ucts from step 1 and 2 were combined, denatured at 94C and annealed for
10 min. to ligate the overlapping complementary nucleotides from the 3
end of the signal peptide and the 5 start of the MP domain and subse-
quently amplified by PCR using primer I and IV. The ProMP mutant was
cloned accordingly, with primer I and 5GCCCGGCTCCACAAACATAGGCA-
GAGGGCTGCCC 3 for the (i) PCR of the signal peptide, and a primer start-
ing at the disintegrin domain 5ATGTTTGTGGAGCCGGGC 3 and primer (IV)
for the (ii) PCR. The empty pexchange vector was transfected into the chon-
drocytic T/C28a4 to serve as control. All plasmids were sequenced com-
pletely in both directions on an automated sequencer (ABI model 373,
Applied Biosystems, Weiterstadt, Germany).
Generation of permanent cell lines transfected
with ADAM15 and domain deletion mutants
The transfection and selection procedures were performed as described
previously [14]. Briefly, T/C28a4 chondrocytic cells were transfected in 6-
well tissue culture plates using JetPei (Biomol, Hamburg, Germany)
according to the manufacturer’s instructions. Twenty-four hours after
transfection, cells were treated with 10 g/ml puromycin and cell foci sur-
viving the antibiotic pressure were pooled, grown to confluency and
checked for protein expression using Western blotting. Cells that were
transfected with the empty pexchange-1 vector served as a control.
Cell culture
Cells were kept in Dulbecco’s modified Eagle’s medium supplemented with
10% heat-inactivated foetal calf serum (FCS) and kept under constant2636 © 2008 The Authors
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antibiotic culture using 3 g/ml puromycin, All tissue culture reagents
were from Gibco/Invitrogen, Karlsruhe, Germany. For all subsequent tests,
cells were grown to subconfluency to a cell density of about 4  10
6
cells/75 cm
2 tissue culture flask.
Generation of the recombinant prodomain 
of ADAM15
The nucleotide sequence 61–642 (amino acid 21–214 encoding the entire
prodomain without the signal peptide) was amplified using pexchange-1
plasmid containing the ADAM15 sequence as template with primers
5CAGGATCCTGGCCGCTCCCAAATAT3 and 5AACTCGAGGGTCTCTGT-
TACCACATCCCG3. The correctness of the amplified nucleotide sequence
was confirmed by sequencing. After digestion with BamHI/XhoI, the PCR
product was cloned into the pGEX 3P vector and expressed as a Gst (glu-
tathione S-transferase) fusion protein in BL21 E. coli (Amersham, GE
Healthcare, Munich, Germany). Protein expression was induced using 
10 mM IPTG for 3 hrs at room temperature and the harvested E. coli were
lysed with Bug Buster protein extraction reagent and benzonase nuclease
according to the supplier’s instructions (Novagen/Merck, Darmstadt,
Germany). The supernatant containing the Prodomain-Gst fusion protein
was incubated with Gst-sepharose (Amersham) for 30 min. at room tem-
perature, thoroughly washed with PBS (150 mM NaCl, pH 7.4, 1 mM
KH2PO4, 3 mM Na2HPO4) containing 1% Triton X-100. Prodomain-Gst 
was eluted with 10 mM reduced glutathione in 50 mM Tris/HCl, pH 8.0,
containing a protease inhibitor cocktail (Roche Diagnostics, Mannheim,
Germany). In order to isolate the Gst-protein, the Gst-sepharose with 
the bound Prodomain-Gst fusion protein was treated with Precission
Protease according to the manufacturer’s instructions (Amersham), thor-
oughly washed with PBS/Triton X-100, and subsequently eluted with the
reduced glutathione buffer. Protein concentration was determined using
bicinchoninic acid (BCA) reagent (Pierce/Thermo Fisher Scientific,
Schwerte, Germany).
Far Western with recombinant prodomain
Collagen type II (2.5 and 5 g) and bovine serum album (BSA, 2.5 g)
were separated by 10% SDS/PAGE (sodium dodecyl sul-
fate/polyacrylamide gel electrophoresis), transferred to nitrocellulose filter,
blocked in PBS containing 0.05% Tween 20, 1% BSA, and incubated with
soluble Pro-Gst fusion protein or the Gst-tag (1 g/ml) overnight at 4C,
incubated with either anti-Gst- (1:2000) or anti-prodomain-IgG (1:2000)
for 2 hrs at room temperature, followed by detection with HRP (horserad-
ish peroxidase)-conjugated secondary antibodies (Dako, Hamburg,
Germany) and developed using a chemiluminiscent reagent (ECL Plus
Western Blotting Detection System, Amersham, Freiburg, Germany).
Binding assay of recombinant Gst-tagged
prodomain using ELISA technique
Ninety-six-well Maxisorp plates (Nunc, Wiesbaden, Germany) were coated
with 10 g/ml native type II collagen (CII) or heat-denatured CII, incubated
overnight at 4C, and blocked with heat-inactivated 0.01% BSA (Fraction V,
Sigma-Aldrich) for 1 hr at 37C. Denatured CII was prepared by heating at
80C for 15 min., quickly added to the wells and kept at 37C overnight.
Soluble recombinant Pro-Gst fusion protein and Gst were added to the
wells at various concentrations from 0 to 250 nM in PBS (volume 100 l)
and incubated overnight at 4C. Plates were washed 3 times with PBS,
incubated with either anti-Gst (1:2000) or antibodies directed against the
prodomain of ADAM15 (1:2000) for 2 hrs at room temperature, washed
again, incubated with HRP-conjugated antibodies (1:2000) for 1 hr at
room temperature and developed with ABTS solution (Roche
Diagnostics). Absorbance was measured at 405 nm. Mean values and
standard deviations were calculated from triplicate determinations and
corrected for non-specific binding of the primary and secondary antibod-
ies on BSA-coated wells.
Cell adhesion assay
Adhesion assays were performed as described previously [15]. Briefly,
ninety-six-well Maxisorp plates (Nunc) were coated with collagen type II 
(5 g/ml) and fibronectin (5 g/ml) overnight at 4C and blocked with heat
denatured 1% BSA for 1 hr at 37C. After trypsinization, cells were adhered
on collagen type II for 1 hr, washed twice with PBS, fixed with 0.1% 
glutaraldehyde and stained with 0.1% crystalviolet solution. The optical
density (OD) was read at 595 nm. Adhesion assays were performed in
quadruplicates and the results shown are representative of least five
independently performed experiments.
Signal transduction during 
adhesion to collagen type II
Twenty-four-well tissue culture plates (Greiner Bio-One, Frickenhausen,
Germany) were coated with 300 l of a 100 g/ml CII solution, completely
dried under a sterile fume hood and stored overnight at 4C. Cells trans-
fected with vector, entire ADAM15 or an ADAM15-mutant lacking the cyto-
plasmic domain, were gently trypsinized, washed twice with PBS to
remove all traces of FCS, counted and resuspended in FCS-free DMEM
medium at a cell density of 1  10
6 cells/ml. The CII-coated wells were
blocked with PBS/1% BSA for 30 min. at 37C. 7  10
5 cells were added
to one well (2 cm
2) and adhered to CII for 15, 30 and 60 min. at 37C. Cells
start to attach to CII after 30–40 min., and are hardly spread after 1 hr
adhesion to CII, so that they can be easily collected from the well. After
each time-point, the plates were put on ice and the cells scraped off, cen-
trifuged for 2 min., 13,000  g at 4C, lysed and immunoblotted using
phosphotyrosine-specific antibodies as described below. Experiments
were performed at least three times by two different investigators.
Preparation of cell lysates and Western blotting
Transfected cells and primary human chondrocytes were washed with
ice-cold PBS, scraped off the tissue culture flask and lysed in RIPA buffer
for 1 hr at 4C (150 mM NaCl, 50 mM Tris/HCl, pH 7.2, 1% Nonidet P40,
1% Triton X-100, 0.25% sodium desoxycholate, 5 mM EDTA containing
a proteinase inhibitor cocktail (according to the supplier¥s formulation
and instruction: 1 tablet/10 ml, Roche Diagnostics) and phosphatase
inhibitor cocktail I and II (10 l/1 ml lysis buffer, Sigma-Aldrich). After
centrifugation for 5 min at 4C, protein concentration was determined
using BCA reagent. Samples were separated by 10% SDS/PAGE, trans-
ferred to nitrocellulose filter and incubated with the respective antibodiesJ. Cell. Mol. Med. Vol 13, No 8B, 2009
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overnight at 4C. Blots were incubated with appropriate HRP-conjugated
antibodies (1:5000, Dako) and developed using the ECL Plus chemilumi-
nescent reagent. Signals were exposed to X-rays films, scanned and 
signal density was measured with ImageJ program (Rasband, W.S., ImageJ,
U.S. National Institutes of Health, Bethesda, MD, USA, http://rsb.info.
nih.gov/ij/, 1997–2007). Before reprobing filters, blots were stripped
with 62.5 mM Tris/HCl, pH 6.8, 2% SDS, 0.1 M -Mercaptoethanol for 
30 min. at 50C.
Preparation of cell lysates and 
co-immunoprecipitation
Cells transfected with vector or full-length ADAM15 were washed with ice-
cold PBS, scraped off the tissue culture flask and lysed in 10mM HEPES,
pH 7.0, 150 mM NaCl, 5 mM EDTA containing 1% Triton X-100 and the
proteinase and phosphatase inhibitor cocktails (10 l/ml lysis buffer) as
described above for 1 hr at 4C. Protein concentration was determined and
diluted to a concentration of 4 mg/ml. Human primary late stage (Mankin
grades 	7) OA chondrocytes that were pooled from five different donors
were lysed as mentioned above. For co-immunoprecipitation experiments,
the mouse monoclonal anti-ADAM15, the goat polyclonal anti-ADAM15
that co-immunoprecipitated identical bands and the antibodies against FAK
(clone 4.47) were incubated with the freshly prepared cell lysates and
Immunopure immobilized Protein G agarose beads (Pierce) under constant
agitation for 90 min. at 4C. The beads were washed 4 times with lysis
buffer, boiled in sample buffer (125 mM Tris/HCl, pH 6,8, 4% SDS, 40%
Glycerol, 10% -Mercaptoethanol, 20 g/ml Bromophenol blue) for 5 min.
at 95C and subjected to SDS/PAGE. Subsequent Western blotting was
performed as described above.
Results
Generation of permanent cell lines expressing
ADAM15 and domain deletion mutants
The multi-domain structure of ADAM15 was analysed using
SMART [17, Simple Modular Architecture Research Tool at
http://smart.embl-heidelberg.de]. The prodomain comprises
amino acids 21–213, whereas the MP-domain localizes to aa
225–405 and the cytoplasmic region covers the carboxyterminal
end between aa 718–814. In order to analyse the functional impact
of the different ADAM15 domains on collagen adhesion or signal
transduction, respective deletion mutants were cloned and stably
expressed in the chondrocyte cell line T/C28a4 as shown in
Fig. 1A. The truncated constructs either lack the aminoterminal
prodomain (Pro), the pro-and MP-domain (ProMP) or consist
of an intact extracellular portion that is still transmembrane-
anchored, however, devoid of its cytoplasmic tail (cyto).
Figure 1B–D shows the expression of the various mutants
detected by Western blotting using four different antibodies. A
polyclonal antibody directed to the cytoplasmic domain of
ADAM15 revealed a strong expression of the full-length ADAM15
at 100 kD (Fig. 1B). The Pro, which lacks the amino acid
residues 21-213, exhibits a reduced electrophoretic mobility cor-
responding to 78 kD and the additional removal of the MP-domain
yields a protein of 50 kD (ProMP). As expected, the cyto-
mutant remained undetectable by the antibody specific for the
cytoplasmic domain that had been deleted in the respective trans-
fected construct (Fig. 1B). The polyclonal antibody with specificity
for the prodomain detected only the full-length ADAM15 and the
cyto at 85 kD (Fig. 1C). The commercially available monoclonal
Fig. 1 Generation of stably transfected cell lines expressing ADAM15 and
deletion mutants lacking certain domains. (A) Schematic overview of the
multi-domain structure of ADAM15 (a) and architecture of the generated
deletions mutants (b–d). (B–D) show immunoblots of cells transfected
with vector (lane V), full-length ADAM15 (lane a), transmembrane-
anchored ADAM15 lacking the cytoplasmic domain ( cyto, lane b) and
ADAM15 lacking the prodomain and both the pro- and metalloproteinase
(MP) domain (lanes c, d) using antibodies against the cytoplasmic domain
(B), against the prodomain (C) and a mouse monoclonal antibody directed
to the extracellular recombinant ADAM15 (D). Blots were stripped and
reprobed with anti-actin IgG (shown exemplarily for one blot).2638 © 2008 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
as well as the polyclonal goat antibodies both originally raised
against the entire recombinant extracellular part of human
ADAM15 only detected the full-length ADAM15 and ADAM15
cyto, thus allowing for the conclusion that their epitope/s local-
ize to the prodomain (aa 21–213). The result is shown for the
monoclonal antibody (Fig. 1D).
The prodomain binds to native collagen type II
The analysis of the different ADAM15 domains using the SMART
program resulted in the prediction of a type II fibronectin collagen-
binding domain (aa 107–134), and a fibronectin type III repeat (aa
65–130), thereby suggesting that the prodomain might confer
binding capabilities to ECM molecules such as collagen. To test
this hypothesis, the prodomain was recombinantly expressed in E.
coli as a fusion protein composed of the prodomain and a Gst-tag
(Pro-Gst). Figure 2A shows a SDS-PAGE and the corresponding
Western blot developed with an anti-Gst antibody that stains the
Pro-Gst fusion protein as a 49 kD band and the cleaved off Gst-tag
at 26 kD in the expected molecular weight. Binding of the Pro-Gst
was performed in a Far Western by incubating a solution of the
fusion protein with a nitrocellulose filter, to which CII and BSA
have been blotted. Strong binding of Pro-Gst to CII could be
detected using antibodies either directed against the prodomain or
the Gst-tag (Fig. 2B and C). However, the detection signal of the
CII band using the antibody against the prodomain was somewhat
weaker compared with the signal detected by the anti-Gst, pre-
sumably because binding of the prodomain to collagen might
affect the accessibility of the anti-prodomain antibody to its epi-
tope. In addition, binding studies of Pro-Gst were performed in
96-well plates coated with native triple helical CII using either anti-
prodomain or anti-Gst antibodies for detection of the bound fusion
protein (Fig. 2B and C). Binding of Pro-Gst was concentration-
dependent and reached a plateau at 125 nM when developed with
anti-Gst, or 250 nM when detected with anti-prodomain antibod-
ies. The destruction of the triple helical conformation of CII by
heat-denaturation abrogated the binding of Pro-Gst completely.
The prodomain is critical for the reinforcement of
collagen adhesion by ADAM15
Chondrocytic cells overexpressing the entire ADAM15 molecule
attach to CII significantly better than vector-transfected control
cells [Ref. 14 and Fig. 3A]. This 2–2.5-fold enhanced binding com-
pared with vector control also applies to chondrocytes transfected
with an ADAM15 mutant lacking the complete cytoplasmic
Fig. 2 Binding of Pro-Gst fusion protein
to native and denatured collagen type II
(CII). (A) SDS/PAGE of the purified 
Pro-Gst at 49 kD and Gst-tag at 26 kD
(lanes  a,  b) and the corresponding
immunoblot using anti-Gst antibodies
(lanes c, d). (B, C) Binding of Pro-Gst to
CII and BSA was performed using 
Far Western Technique. After elec-
trophoretic separation on a 10% poly-
acrylamide gel, CII (5, 2.5 g, lanes a,
b; 5 g, lanes d, f) and BSA (5 g, lanes
c, e, g) were transferred to a nitrocellu-
lose filter, incubated with Pro-Gst and
detected with anti-Gst (B) and anti-
prodomain antibodies (C). Incubation
with the Gst-tag alone is shown in (B, C;
lanes d, e). Controls were performed
without addition of Pro-Gst, but using
the detection antibodies (B, C; lanes f,
g). Using ELISA technique, soluble Pro-
Gst (0–250 nM) was incubated on
immobilized native CII () or denatured
CII () and detected with anti-Gst (B) or
anti-prodomain antibodies (C).  B,  
incubation of the Gst-tag with native CII.
Mean values and standard deviation
from triplicates are shown.J. Cell. Mol. Med. Vol 13, No 8B, 2009
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domain, indicating that this intracellular part is dispensible for the
proadhesive effect of ADAM15 on chondrocyte interaction with CII
(Fig. 3B). However, cells expressing a truncated ADAM15 mutant
devoid of its prodomain lose their capability of an enhanced colla-
gen binding. The additional deletion of the MP domain (ProMP)
resulted in a further impairment of CII binding of 25–30% as com-
pared with the vector control (Fig. 3C). All transfected cells did not
exhibit any statistically significant difference in their binding abil-
ity to fibronectin. No attachment to BSA was observed.
The cytoplasmic domain is involved in 
ADAM15-dependent signal transduction 
during adhesion to collagen type II
Vector-, ADAM15- and ADAM15  cyto-transfected cells were
plated on CII for 15, 30, 45 and 60 min under strict serum-free
conditions and analysed for tyrosine-phosphorylated proteins 
by Western blot with a pan tyr-phospho antibody. Under these
Fig. 3 ADAM15 and ADAM15 cyto
exhibit reinforced binding to collagen
type II (CII). Cells were adhered at vari-
ous densities to CII, fibronectin and
BSA. (A) Shown are results of represen-
tative adhesion experiments using vec-
tor-transfected control cells (solid bar)
and ADAM15-transfected cells (open
bar). (B) Cells expressing only the
transmembrane-anchored extracellular
part of ADAM15 (cyto) also show
stronger binding to CII compared with
the control cells. (C) Cells expressing
ADAM15 without the prodomain ( pro)
exhibited the same binding to CII as
control, and the additional removal of
the MP-domain ( ProMP) consistently
reduced cell adhesion to about 25%
below the level of vector control cells.
All cells transfected with ADAM15 and
the deletion constructs did not exhibit
enhanced binding to fibronectin com-
pared with the vector control cells and
none of the cells exhibited binding to
BSA (shown exemplarily for ADAM15-
and cyto-transfected cells). Values are
the mean and standard deviations of
quadruplicates.2640 © 2008 The Authors
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adhesion conditions, the T/C28a4 chondrocytes attach very
loosely to the collagen-coated wells, stay round-shaped up to
30–40 min. and start to spread very slightly after 60 min. of adhe-
sion (not shown). Differences of staining intensities of phospho-
protein bands between vector control and the ADAM15-trans-
fected cells were discernible very prominently in the molecular
weight ranges of 120–130 kD as well as 60–80 kD (Fig. 4A). The
phosphorylation pattern of the cells expressing ADAM15 without
the cytoplasmic tail, however, remained unchanged compared
with vector control, thus indicating an involvement of the cyto-
plasmic domain in the transduction of ADAM15-dependent signals
during collagen adhesion (Fig. 4B).
FAK is less phosphorylated at its 
autophosphorylation site in ADAM15-transfected
cells during adhesion to CII
We analysed the possibility of a modulation of the phophorylation
state of FAK by ADAM15 overexpression, because FAK plays a piv-
otal role in adhesion processes and has a known molecular weight
of 125 kD corresponding to the above mentioned molecular
weight range of ADAM15-dependent differences in phospho signal
intensities. Chondrocytic cells expressing ADAM15, ADAM15 
cyto and the vector control were adhered to immobilized CII and
the phosphorylation of FAK at its autophosphorylation site Y397
[18] was analysed after 15, 30 and 60 min. of attachment. Both
the vector- and ADAM15-transfected cells did activate FAK in the
adhesion process, but the phosphorylation signal at Y397 was
two- to three-fold lower in the ADAM15-transfected cells than in
the vector control (Fig. 5A). The same set of experiments was
  performed on cells transfected with the ADAM15  cyto and the
Fig. 5 Adhesion to CII results in a reduced phosphorylation of focal adhe-
sion kinase (FAK) at Y397 in ADAM15 expressing cells. Cells were
adhered to CII and lysed after 15, 30 and 60 min. Cell lysates (40 g)
were applied to SDS/PAGE and immunoblotted using anti-pY397 FAK
antibodies. (A) ADAM15 ()-transfected cells exhibit a 2–3 times
reduced phosphorylation of FAK compared with vector control (
) cells,
whereas (B) ADAM15  cyto expressing cells (C) show an identical
activation of FAK during adhesion. As loading control, all filters were
stripped and reprobed with anti-FAK antibodies and expression of
ADAM15 and ADAM15  cyto was controlled using anti-ADAM15 anti-
bodies. Optical density of the bands was analysed using ImageJ software
and normalized to non-phosphorylated FAK expression.
Fig. 4 Protein tyrosine phosphorylation during adhesion to collagen type
II. ADAM15 and ADAM15 cyto and vector-transfected cells were
adhered under serum-free conditions to CII and lysed after 15, 30, 45
and 60 min. Cell lysates (50 g) were electrophoresed, blotted and
developed using a pan tyrosine phosphorylation antibody (pTyr99). (A)
ADAM15-transfected cells () exhibit a prominently reduced phospho-
rylation signal in the molecular weight range of 120–130 kD compared
with vector-transfected cells (
), whereas (B) ADAM15 cyto cells (C)
show no different phosphorylation signals intensities in this molecular
weight range. Actin served as a loading control. The experiments were
repeated at least three times.J. Cell. Mol. Med. Vol 13, No 8B, 2009
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signal intensities of the phosphorylated Y397 of FAK remained
unchanged compared with the vector control cells (Fig. 5B), indi-
cating in agreement with the above-described results a critical role
of the cytoplasmic domain in ADAM15-dependent signals during
collagen adhesion. To control equal loading, blots were reprobed
with anti-FAK antibodies and the expression of ADAM15 and/or
ADAM15  cyto was verified with ADAM15-specific antibodies.
ADAM15 and FAK co-immunoprecipitate with
each other
Based on the modulatory effect of ADAM15 on FAK phosphoryla-
tion, we further analysed the possibility of an underlying
  protein–protein interaction between both molecules. Accordingly,
co-immunoprecipitation studies were performed on ADAM15- and
vector-transfected T/C28a4 chondrocytes using ADAM15- and
FAK-specific antibodies for selective protein precipitation and sub-
sequent Western blot analyses. ADAM15 protein can be precipi-
tated specifically only in the ADAM15 expressing cells () using
the mouse monoclonal anti-ADAM15 antibody (Fig. 6A, left panel)
and accordingly, FAK co-immunoprecipitates in ADAM15- (), but
not in the vector-transfected cells (–) (Fig. 6A, right panel).
Conversely, co-immunoprecipitation was also performed by cap-
turing FAK with a specific monoclonal antibody in the first step fol-
lowed by the detection of the FAK-associated ADAM15 protein in
ADAM15-transfected () only, but not in the control cells (–) (Fig. 6B,
right panel). The anti-FAK monoclonal antibody can precipitate
FAK from both vector and ADAM15-transfected cells (Fig. 6B, left
panel). Additional experiments demonstrate that the interaction of
ADAM15 with FAK is not restricted to the human cell line, but is
also detectable in primary human OA chondrocytes obtained from
late-stage disease (Fig. 7B). Although FAK is expressed in normal
as well as in OA chondrocytes, ADAM15 expression remains clearly
confined to OA chondrocytes (Fig. 7A and ref [9]).
Discussion
The recently uncovered proadhesive effects of ADAM15 in chon-
drocyte binding to CII associated with an anti-apoptotic function
[14] have provoked the present study aiming at the characteriza-
tion of functional domains that might confer such homeostatic
effects of ADAM15 in cell–matrix interactions. The stable expres-
sion of ADAM15 as well as certain deletion mutants lacking
selected subdomains of the multi-modular molecule in T/C28a4
chondrocytes allowed us to identify the prodomain as critical for
the reinforcement of cell adhesion to CII. Moreover, upon expres-
sion as a recombinant bacterial protein a direct interaction with CII
could be demonstrated. This result was not a priori predictable
despite its accordance with our preceding elucidation of so far
unknown potential ECM-interaction sites by an in silico analysis of
the prodomain sequence. Thus, the involvement in cell adhesion
is an unexpected new facet of prodomain function because its
established role in ADAM family homologues as well as in the
closely related matrix metalloproteinases is to keep the MP
domain in a catalytically inactive conformation [1]. In addition,
there is clear evidence for a role of prodomains in proper protein
folding in the endoplasmatic reticulum and for ADAM12 and 17
[19, 20] but not ADAM10 [21]. This chaperone function is even
required for cell membrane expression. Although the potential role
of the ADAM15-prodomain as a chaperone is unclear so far, it is
however not imperative for ADAM15 cell surface expression.
Thus, we could show by cell surface biotinylation that ADAM15
mutants lacking the prodomain (Pro and ProMP) are
expressed on the cell surface (data not shown) in accordance with
the previously published data on ADAM10 [21]. Of course, the
surface expressions of the Pro and ProMP constructs do not
prove the lack of any chaperone function of the ADAM15
Fig. 6 ADAM15 interacts with FAK. Co-immunoprecipitation (IP) experi-
ments were performed in vector- (
) and ADAM15-transfected cells ()
by using either anti-ADAM15 or anti-FAK antibodies for selective protein
precipitation followed by immunoblotting (IB) with a polyclonal anti-
ADAM15 antibody directed against the cytoplasmic tail or a monoclonal
anti-FAK. (A) ADAM15 precipitates specifically with the mouse mono-
clonal anti-ADAM15 in the ADAM15 expressing cells only (left panel) and
FAK is co-immunoprecipitated with ADAM15 (right panel). (B) Using
anti-FAK antibodies, FAK is precipitated in cell lysates from vector- and
ADAM15-transfected cells (left panel) and ADAM15 co-immunoprecipi-
tates with FAK in ADAM15 expressing cells only (right panel).2642 © 2008 The Authors
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prodomain because our experiments cannot exclude an unproper
folding of the mutant proteins in the cell membrane. Accordingly,
the ADAM15
MP domain expressed on the surface of cells trans-
fected with the Pro constructs could be affected by the misfold-
ing as well. Because an unproperly folded MP domain might also
contribute to the observed loss of enhanced collagen binding in
the respective transfectants, our results do not allow for the con-
clusion that the collagen-interacting properties of ADAM15 reside
exclusively in its prodomain. However, in accordance with the
adhesion experiments in the Pro-transfected chondrocytes the
direct collagen binding of the recombinant prodomain clearly sup-
ports its functional role in matrix interactions. The prodomain in
ADAM15 spans a region of approximately 200 amino acid residues
and sequence comparison with the prodomains of other ADAMs
reveals only a minor degree of homology (about 30% sequence
identity and a maximum of 40–50% homology), suggesting that
the newly unravelled function in cell adhesion might remain a
unique ADAM15-specific property. A likewise new function to the
well-known role in preserving the inactive conformation of the MP
domain has more recently been described for the ADAM10
prodomain. Thus, the soluble recombinant ADAM10 prodomain
was shown to efficiently and specifically inhibit ADAM10 prote-
olytic activity thereby proving its regulatory capacity on cellular
shedding events even after removal from the catalytic domain
upon activation [22]. Although our results using the overexpres-
sion of deletion mutants that lack the prodomain provide unequiv-
ocal evidence for its critical role in the reinforcement of adhesion
to CII, analogous studies on the cytoplasmic tail revealed its dis-
pensibility in this respect. It is therefore indicated that an outside-
in signal via the cytoplasmic domain is not required for the proad-
hesive effect of ADAM15 that is conferred by its ectodomain.
However, the cytoplasmic tail that harbours signalling motifs, such
as src homology 3 (SH3) ligand domains, has already been char-
acterized for its potential to participate in phosphorylation-
dependent interactions with src family protein tyrosine kinases
[23, 24]. Accordingly, our studies clearly show that during chon-
drocyte adhesion to CII the pattern of protein tyrosine phosphory-
lation is altered in ADAM15 overexpressing T/C28a4 cells in
dependency on the presence of the cytoplasmic domain.
Moreover, our studies provide first experimental evidence for the
modulation of CII adhesion-dependent FAK phosphorylation by
ADAM15. FAK is ubiquitously expressed and central to the integra-
tion of growth factor receptor and ECM signals by forming a sig-
nalling scaffold that is involved in growth, differentiation and sur-
vival pathways in many different cell types [18, 25]. FAK is main-
tained in an inactive and autoinhibited state and gets activated via
autophosphorylation at tyrosine 397 (Y397) by the engagement of
integrins with the ECM [26]. Phosphorylated Y397 provides a
binding site for c-Src, and the subsequent interaction of Src with
FAK sustains both protein kinases in their activated states thereby
giving rise to the initiation of further downstream signalling cas-
cades [27]. Contrary to the expectations based on the well-estab-
lished FAK activation by integrin-mediated ECM engagement, the
enhanced binding of ADAM15-transfected chondrocytes to CII 
is not mirrored by an enhanced phosphorylation of FAK during 
CII-attachment. Our results provide clear evidence for the down-
regulation of the phosphorylation signal at the critical autophos-
phorylation site Y397 of FAK by ADAM15 during CII adhesion
thereby indicating a decoupling of cell attachment from FAK sig-
nalling. The reciprocal co-immunoprecipitation of ADAM15 and
FAK not only in T/C28a4 cells but also in primary human chondro-
cytes from OA cartilage suggests their presence in a protein com-
plex that is likely formed during CII adhesion in the focal contacts
thereby leaving the possibility of a direct protein–protein interac-
tion an open option although it cannot be excluded that one or
more bridging intermediate protein(s) might be involved as well.
Because FAK phosphorylation is a part of the integrin-mediated
mechanotransduction [28], it is conceivable that the newly uncov-
ered modulatory effect of ADAM15 might affect the perception of
the mechanical forces in the cartilage matrix by the chondrocyte.
Thus, it remains an intriguing possibility that the up-regulation of
ADAM15 in degenerative joint disease [10] might contribute to an
Fig. 7 In primary cells from human OA cartilage FAK interacts with
ADAM15 that is not expressed in normal human chondrocytes. (A) Cell
lysates (50 g) of normal (lane a) and OA chondrocytes from 2 different
donors (lanes b, c) were applied to SDS/PAGE and immunodetected
using anti-ADAM15 and anti-FAK antibodies. Actin served as a loading
control. (B) Left panel, FAK could be co-immunoprecipitated from pooled
lysates of OA-chondrocytes using anti-ADAM15 antibodies, right panel,
ADAM15 co-precipitates specifically with FAK. As control isotype specific
IgG were used.J. Cell. Mol. Med. Vol 13, No 8B, 2009
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adaptation of the outside-in signalling in the chondrocytes to the
elevated mechanical forces that arise from the increased catabo-
lism in the ECM already at early stages of OA [29]. Although this
scenario is conceivable to apply to the attenuation of the FAK-
Y397 phosphorylation signal in integrin-dependent collagen adhe-
sion, it is unlikely that this hypothesis could explain all facets of
ADAM15-mediated cell protective effects, e.g. the enhanced
resistance to growth factor starvation and will have to be
addressed in future studies. In addition, functional studies of
genetically manipulated chondrocytes imply that not all pheno-
typic characteristics of articular chondrocytes remain conserved
under such experimental conditions. Accordingly, the respective
conclusions on OA-pathogenesis inferred by the present investi-
gations in a human chondrocyte line remain somehow restrained
by the respective limitations of the in vitro model.
The present investigation, however, provides unequivocal evi-
dence for a so far unknown CII-binding property of the ADAM15
prodomain and its crucial role in the reinforced collagen adhesion
of ADAM15 overexpressing chondrocytes. Moreover, our studies
uncover in these cells an uncoupling between the enhanced CII
adhesion and a concomitantly reduced phosphorylation signal at
the critical FAK-autophosphorylation site Y397. The proadhesive
effect associated with the prodomain and the alteration of outside-
in signalling conferred by the cytoplasmic tail are likely contribut-
ing to the earlier described [14] homeostatic functions of ADAM15
in the matrix metabolism of OA cartilage.
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